Eur Rev Med Pharmacol Sci 2022; 26 (18): 6700-6724

DOI: 10.26355/eurrev_202209_29771

EMMPRIN is an emerging protein capable of regulating cancer hallmarks

B. de la Cruz Concepción, L.D. Bartolo-García, M.D. Tizapa-Méndez, M. Martínez-Vélez, J.J. Valerio-Diego, B. Illades-Aguiar, E.G. Salmerón-Bárcenas, J. Ortiz-Ortiz, F.I. Torres-Rojas, M.Á. Mendoza-Catalán, N. Navarro-Tito, A.E. Zacapala-Gómez

Laboratorio de Biomedicina Molecular, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México. zak_ana@yahoo.com.mx


EMMPRIN, also known as Basigin or CD147, is a transmembrane glycoprotein member of the immunoglobulin superfamily. It is expressed basally in cells that regulate physiological processes of the cardiovascular, nervous, and immune systems. However, EMMPRIN is also capable of interacting with different proteins, like VEGFR, SMAD4, Integrin, MCT, CyPA, GLUT1, CAIV, Annexin II, Cav-1, CAML, etc., and regulating signaling pathways that stimulate the cell processes of proliferation, apoptosis, metabolism, adhesion, invasion, migration, metastasis, tumor immune response, and angiogenesis processes, which favors the development of different types of cancer. EMMPRIN is the first protein reported that favors cancer development due to its ability to interact with extracellular, intracellular, and membrane proteins. In conclusion, EMMPRIN regulates several proteins associated with the development of tumor processes. Therefore, blocking the expression of EMMPRIN can be a therapeutic target, and the analysis of its expression can be used as an important biomarker in cancer.

Free PDF Download

To cite this article

B. de la Cruz Concepción, L.D. Bartolo-García, M.D. Tizapa-Méndez, M. Martínez-Vélez, J.J. Valerio-Diego, B. Illades-Aguiar, E.G. Salmerón-Bárcenas, J. Ortiz-Ortiz, F.I. Torres-Rojas, M.Á. Mendoza-Catalán, N. Navarro-Tito, A.E. Zacapala-Gómez
EMMPRIN is an emerging protein capable of regulating cancer hallmarks

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 18
Pages: 6700-6724
DOI: 10.26355/eurrev_202209_29771